14 September 2005

Contents

Editorial

• Volume 6 Number 9 September 2005

Conference reports

• 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil

• Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy

• Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS

• New drugs in pregnancy: atazanavir; T20

• Lopinavir/r use in children less than two years old – promising results despite low plasma levels

• Favourable outcomes in children treated with HAART in the MSF programmes

• Encouraging results with cut up generic fixed dose combination tablets in Uganda

• Predictors of survival at three years follow up for HIV-infected children in Cote D’Ivoire

• Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results

• T20 (enfuvirtide) studies presented at Rio

• Strategies for salvage therapy

• Antiviral activity of foscarnet in salvage patients

• Novel strategies with existing drugs

• Antiretroviral activity of new and novel agents

• Overview of pharmacology studies

• Incidence of TB infection despite HAART and treatment in coinfected patients

• Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients

• Does WHO clinical stage reliably predict who should receive ARV treatment?

• Continuous vs intermittent treatment with triple nuke combination of AZT/3TC/tenofovir in Africa: early results from DART study

Treatment access

• Global Fund commitment to $175M annually in 2006, 2007

Guidelines

• UK treatment guidelines online (2005)